Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

被引:2
|
作者
Vaishampayan, Ulka N. [1 ]
Muzaffar, Jameel [2 ]
Winer, Ira [3 ]
Rosen, Seth D. [4 ]
Hoimes, Christoper J. [5 ,6 ]
Chauhan, Aman [7 ]
Spreafico, Anna [8 ]
Lewis, Karl D. [9 ]
Bruno, Debora S. [10 ,11 ]
Dumas, Olivier [12 ]
Mcdermott, David F. [13 ]
Strauss, James F. [14 ]
Chu, Quincy S. [15 ]
Gilbert, Lucy [16 ]
Chaudhry, Arvind [17 ]
Calvo, Emiliano [18 ]
Dalal, Rita [19 ]
Boni, Valentina [18 ]
Ernstoff, Marc S. [20 ]
Velcheti, Vamsidhar [21 ]
机构
[1] Univ Michigan, Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA
[2] Duke Univ, Sch Med, Dept Med, Durham, NC USA
[3] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[4] Hematol Oncol Assoc Treasure Coast, Port St Lucie, FL USA
[5] Univ Hosp Cleveland, Case Comprehens Canc Ctr, Phase Program 1, Cleveland, OH 44106 USA
[6] Duke Univ, Duke Canc Inst, Durham, NC USA
[7] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Princess Margaret Hosp Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada
[9] Univ Colorado, Sch Med, Aurora, CO USA
[10] Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, Dept Pharm, Cleveland, OH USA
[11] Case Western Reserve Univ, Cleveland, OH USA
[12] Univ Laval, CHU Quebec, Quebec City, PQ, Canada
[13] Beth Israel Deaconess Med Ctr, Boston, MA USA
[14] Mary Crowley Canc Res Ctr, Dallas, TX USA
[15] Univ Alberta, Cross Canc Inst, Alberta Hlth Serv, Edmonton, AB, Canada
[16] McGill Univ, Ctr Hlth, Div Radiat Oncol, Hlth Ctr, Montreal, PQ, Canada
[17] Summit Canc Ctr, Spokane, WA USA
[18] START Madrid CIOCC, Ctr Integral Oncol Clara Campal, Madrid, Spain
[19] Mural Oncol Inc, Waltham, MA USA
[20] NCI, Div Canc Treatment & Diag, NIH, Bethesda, MD 20814 USA
[21] NYU, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
关键词
Cytokine; Immunotherapy; Solid tumor; Skin Cancer; Ovarian Cancer;
D O I
10.1136/jitc-2024-010143
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Nemvaleukin alfa (nemvaleukin, ALKS 4230) is a novel, engineered cytokine that selectively binds to the intermediate-affinity interleukin-2 receptor, preferentially activating CD8+ T cells and natural killer cells, with minimal expansion of regulatory T cells, thereby mitigating the risk of toxicities associated with high-affinity interleukin-2 receptor activation. Clinical outcomes with nemvaleukin are unknown. ARTISTRY-1 investigated the safety, recommended phase 2 dose (RP2D), and antitumor activity of nemvaleukin in patients with advanced solid tumors.Methods This was a three-part, open-label, phase 1/2 study: part A, dose-escalation monotherapy, part B, dose-expansion monotherapy, and part C, combination therapy with pembrolizumab. The study was conducted at 32 sites in 7 countries. Adult patients with advanced solid tumors were enrolled and received intravenous nemvaleukin once daily on days 1-5 (21-day cycle) at 0.1-10 mu g/kg/day (part A), or at the RP2D (part B), or with pembrolizumab (part C). Primary endpoints were RP2D selection and dose-limiting toxicities (part A), and overall response rate (ORR) and safety (parts B and C).Results From July 2016 to March 2023, 243 patients were enrolled and treated (46, 74, and 166 in parts A, B, and C, respectively). The maximum tolerated dose was not reached. RP2D was determined as 6 mu g/kg/day. ORR with nemvaleukin monotherapy was 10% (7/68; 95% CI 4 to 20), with seven partial responses (melanoma, n=4; renal cell carcinoma, n=3). Robust CD8+ T and natural killer cell expansion, and minimal regulatory T cell expansion were observed following nemvaleukin treatment. ORR with nemvaleukin plus pembrolizumab was 13% (19/144; 95% CI 8 to 20), with 5 complete and 14 partial responses; 6 responses were in PD-(L)1 inhibitor-approved and five in PD-(L)1 inhibitor-unapproved tumor types. Three responses were in patients with platinum-resistant ovarian cancer. The most common grade 3-4 treatment-related adverse events (TRAEs) in parts B and C, respectively, were neutropenia (49%, 21%) and anemia (10%, 11%); 4% of patients in each part discontinued due to TRAEs.Conclusions Nemvaleukin was well tolerated and demonstrated promising antitumor activity across heavily pretreated advanced solid tumors. Phase 2/3 studies of nemvaleukin are ongoing.Trial registration number NCT02799095.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] An open-label phase 1 trial of lenvatinib plus pembrolizumab in patients with advanced selected solid tumors
    Kitano, Shigehisa
    Fujiwara, Yutaka
    Shimizu, Toshio
    Iwasa, Satoru
    Yonemori, Kan
    Kondo, Shunsuke
    Shimomura, Akihiko
    Koyama, Takafumi
    Ebata, Takahiro
    Iizumi, Sakura
    Ikezawa, Hiroki
    Namiki, Masayuki
    Kubota, Tomoki
    Miura, Takuma
    Yamamoto, Noboru
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.
    McKean, Meredith
    Hutson, Thomas E.
    Piha-Paul, Sarina A.
    Micaily, Ida
    Liao, Mingxiang
    Humphreys, Robin
    Brock, Graham
    Sahr, Natasha
    Amber, Vian
    Spira, Alexander I.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
  • [44] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael Sangmin
    Wolf, Ido
    Fakih, Marwan
    De Vos-Geelen, Judith De
    Lee, Valerie
    Vogel, Arndt
    Wu, Larry
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors
    Kelley, Robin Kate
    Van Cutsem, Eric
    Lee, Michael S.
    Wolf, Ido
    Fakih, Marwan
    de Vos-Geelen, Judith
    Lee, Valerie
    Vogel, Arndt
    Wu, Xi Lawrence
    Jin, Fan
    Naik, Girish S.
    O'Reilly, Eileen Mary
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [46] TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial
    Naing, Aung
    Mckean, Meredith
    Tolcher, Anthony
    Victor, Anja
    Hu, Ping
    Gao, Wei
    Filho, Marco A. F. Nogueira
    Kitzing, Thomas
    Gleicher, Stephan
    Holland, Daniel
    Richter, Emilia
    Tadjalli-Mehr, Keyvan
    Siu, Lillian L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (02)
  • [47] THERAPY OF ADVANCED SOLID TUMORS IN MICE USING CHEMOTHERAPY IN COMBINATION WITH INTERLEUKIN-2 WITH AND WITHOUT LYMPHOKINE-ACTIVATED KILLER CELLS
    KEDAR, E
    BENAZIZ, R
    SHILONI, E
    ISRAEL JOURNAL OF MEDICAL SCIENCES, 1988, 24 (9-10): : 494 - 504
  • [48] PHASE 1/2 STUDY OF THOR-707 (SAR444245), A PEGYLATED RECOMBINANT NON-ALPHA IL-2, AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB OR CETUXIMAB IN PATIENTS (PTS) WITH ADVANCED SOLID TUMORS
    Falchook, Gerald
    Gan, Hui
    Fu, Siqing
    McKean, Meredith
    Azad, Arun
    Sommerhalder, David
    Wang, Judy
    Tan, Tira
    Chee, Chen
    Barve, Minal
    Lemeque, Charlotte
    Acuff, Nicole
    Pham, Helene
    Mooney, Jill
    Wang, Rui
    Marina, Neyssa
    Abbadessa, Giovanni
    Meniawy, Tarek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A511 - A511
  • [49] A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
    Ulahannan, Susanna Varkey
    Powderly, John D.
    Johnson, Melissa Lynne
    Krauss, John C.
    Sharma, Manish
    Davar, Diwakar
    Karasic, Thomas Benjamin
    Gaillard, Stephanie
    Jenkins, Yonchu
    Stagg, Robert J.
    Bomba, Darrin
    Standifer, Nathan
    Smith, Steven
    Prasit, Peppi
    Dubensky, Thomas Walter
    Whiting, Sam H.
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
    Xu, Jianming
    Cui, Jiuwei
    Jiang, Haiping
    Zeng, Yan
    Cong, Xiuyu
    CANCER MEDICINE, 2023, 12 (07): : 7762 - 7771